Gold prices steady ahead of Fed decision; weekly weakness noted
On Thursday, Benchmark analysts increased the price target for Nutex Health (NASDAQ: NUTX) shares to $300 from the previous $150, while sustaining a Buy rating for the stock. The adjustment follows Nutex Health’s significant first-quarter earnings, which surpassed expectations. According to InvestingPro data, the stock has delivered an impressive 2,111.7% return over the past year, with a current P/E ratio of 10.62x.
Nutex Health reported a first-quarter revenue of $211.8 million, a 214% increase year-over-year, which was notably higher than Benchmark’s estimate of $121 million. The revenue surge was mainly attributed to favorable outcomes in rate arbitrations with payors under the No Surprise Act independent dispute resolution process, contributing approximately $105 million compared to the estimated $35 million. The company maintains strong financial health with a 51.95% gross profit margin and a comfortable current ratio of 2.27, as reported by InvestingPro.
The company’s claims submission strategy proved effective, with about two-thirds of claims going to arbitration during the first quarter, achieving a success rate of over 80%, similar to the fourth quarter’s performance. The analyst noted that the consistency of these results provides greater clarity on the sustainability of Nutex’s rate realization.
The positive financial outcome has also led to an optimistic forecast for the fiscal years 2025 and 2026, with upward revisions to revenue, adjusted EBITDA, and GAAP EPS expectations. Cash flow has seen a robust recovery as the company experiences a decrease in the lag time for recoveries.
Operationally, Nutex is performing well with a 20.5% increase in patient visits for established hospitals and 5.3% for those in operation for a longer time. The company is also on schedule with its expansion plans, expecting to open three new hospitals in the second half of 2025.
The new price target of $300 is based on a projected FY25 enterprise value to EBITDA ratio of 6.1 times, which is considered a discount when compared to the hospital peer group. Nutex Health continues to be a top pick for Benchmark, branded as a "Benchmark Best Idea." InvestingPro’s comprehensive analysis indicates the stock is currently overvalued, with 11 additional ProTips available to subscribers, including detailed insights on cash flow strength and financial health metrics.
In other recent news, Nutex Health Inc. reported a significant 214% increase in total revenue for Q1 2025, reaching $211.8 million, compared to the same period last year. The company’s adjusted EBITDA improved substantially to $72.8 million from a previous loss, while net income rose to $14.6 million, or $2.65 per basic share. Nutex Health plans to expand further by opening three new hospitals in Texas later in 2025. The company’s strategic focus on operational efficiencies and its micro-hospital model has been a key driver of its financial success. Additionally, the arbitration process has played a crucial role in revenue recognition, with a high success rate in collections. Nutex Health maintains a strong balance sheet, with cash and cash equivalents increasing by 44.1% from the end of 2024. The company is also exploring technology investments, including artificial intelligence, to enhance operational efficiencies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.